U.S. Self-monitoring Blood Glucose Devices Market Size & Share 2025 - 2034

U.S. Self-monitoring Blood Glucose Devices Market Size

The U.S. self-monitoring blood glucose devices market was valued at USD 7 billion in 2024 and is projected to grow from USD 7.6 billion in 2025 to USD 20.3 billion by 2034, expanding at a CAGR of 11.6% during the forecast period, according to the latest report published by Global Market Insights Inc. This steady growth is stimulated by various factors such as growing prevalence of diabetes across the U.S., rising technological advancements in self-monitoring blood glucose devices, policy and reimbursement support.

Self-monitoring blood glucose devices are medical instruments used by individuals with diabetes to measure and monitor their glucose levels regularly. These devices enable patients to manage their condition effectively by providing data on blood sugar levels, helping them make informed decisions about diet, physical activity, and medication. Major companies in the industry include F. Hoffmann-La Roche, Abbott Laboratories, Ascensia Diabetes Care Holdings, LifeScan, and Sinocare.
 

The market grew from USD 5.4 billion in 2021 to USD 6.4 billion in 2023, this growth is accelerated by the rising prevalence of diabetes in the U.S. The increasing number of diabetes diagnoses has elevated the demand for effective monitoring and management tools. Self-monitoring blood glucose (SMBG) devices enable patients to monitor blood glucose levels, making them essential for diabetes management. The growing diabetes burden continues to stimulate expansion and development in the SMBG devices market in the U.S.
 

Moreover, government initiatives such as Medicare and Medicaid, along with private insurance providers, are increasingly covering advanced diabetes technologies such as self-monitoring blood glucose (SMBG) devices. This financial support helps reduce out-of-pocket expenses for patients, encouraging healthcare providers to adopt and recommend these devices. Therefore, more individuals gain access to high-quality diabetes management tools, boosting the market. 
 

For instance, in 2021, U.S. state Medicaid programs spent approximately USD 76.6 billion on diabetes-related medical costs, averaging USD 8,771 per person. These economic incentives further promote the adoption of advanced monitoring solutions, reinforcing their importance in improving patient outcomes and managing healthcare costs effectively.
 

Self-monitoring blood glucose (SMBG) devices are tools that allow individuals with diabetes to regularly check their own blood glucose levels to make informed decisions about their treatment, diet, and physical activity. These devices, such as blood glucose meters, typically require a small blood sample obtained via a lancet, a test strip, and the meter to display a blood glucose reading.
 

U.S. Self-monitoring Blood Glucose Devices Market Trends

• Remote care delivery has become an increasingly essential aspect of healthcare in recent years, particularly during the ongoing aftermath of the COVID-19 pandemic. SMBG devices that connect with mobile applications or cloud-based platforms enable patients and providers to share real-time glucose values, ultimately improving patient engagement and facilitating virtual consultations, thereby making diabetes easier and more accessible.
   
• SMBG devices are often part of large digital health environments, including electronic health records (EHRs). This interoperability allows for data to be shared continuously and provides predictive insights to clinicians so they can make decisions based on the most current data. Access to this data and the ability to share data support important principles of value-based care by promoting improved outcomes and effective delivery of care.
   
• Moreover, value-based care models focus on improving the health of the patient while decreasing the prolonged costs associated with healthcare. SMBG devices are integral to this, as they alert patients about fluctuations in glucose levels, which helps reduce complications and reliance on emergency care and hospitalizations. These factors serve to improve self-management of diabetes and lower costs over a period of time.
   
• Thus, as healthcare systems increasingly prioritize cost-effective and outcome-driven solutions, the demand for reliable, remote-capable SMBG devices continues to rise. These technologies not only empower patients to manage their condition independently but, also provide clinicians with the tools needed for continuous monitoring and timely intervention.
   
• Therefore, the growth of technology, remote care, and value-based health models is accelerating the adoption of SMBG devices in the U.S. market.
   

U.S. Self-monitoring Blood Glucose Devices Market Analysis

Based on product, the market is segmented into self-monitoring blood glucose meters and consumables. The consumables segment is further bifurcated into testing strips and lancets. The consumables segment held leading position in the market, accounting for USD 4.2 billion in 2024.  
 

• Self-monitoring blood glucose devices require test strips and lancets as essential consumables for daily diabetes management. These consumables are available over-the-counter, ensuring easy access for patients.
   
• Test strips are the primary consumable component. These single-use consumable collect blood samples for glucose measurement. Their compact and lightweight design enables convenient blood sugar monitoring across various locations, including home, workplaces, and during travel.
   
• For instance, AgaMatrix's WaveSense Presto Test Strips, compatible with their WaveSense Presto blood glucose monitoring system, offer reliable performance at competitive prices. Such products contribute to the growth of the consumables segment in the SMBG devices market. The recurring nature of consumable use, combined with easy availability, generates consistent demand and revenue.
   
• While test strips remain crucial, lancet designs continue to evolve for user comfort. Improvements in needle technology have enhanced blood sampling safety and tolerance, improving the overall user experience.
   
• Thus, the consumables segment, particularly test strips, remains fundamental to the SMBG devices market growth. The combination of accessibility, reliability, and technological improvements supports increased adoption and enhanced diabetes management.
   

Based on applications, the U.S. self-monitoring blood glucose devices market is segmented into type 1 diabetes, type 2 diabetes, and gestational diabetes. The type 1 diabetes segment accounted for revenue share of 20.4% in 2024.
 

• Type 1 diabetes is an autoimmune disorder where the immune system attacks and destroys insulin-producing beta cells in the body. This results in insufficient insulin production, affecting the regulation of blood glucose levels.
   
• For individuals with Type 1 diabetes, self-monitoring of blood glucose (SMBG) is essential for disease management. Blood glucose monitoring systems enable multiple daily measurements, allowing patients to make informed decisions about insulin dosage, diet, and physical activity. SMBG glucose meters and test strips facilitate accurate monitoring throughout the day, helping detect blood sugar fluctuations early and reduce the risk of serious complications.
   
• For instance, according to the American Diabetes Association, approximately 2 million Americans lived with Type 1 diabetes in 2021, including 304,000 children and adolescents. This data indicates a substantial patient population requiring blood glucose monitoring.
   
• Thus, the increasing prevalence of Type 1 diabetes, coupled with the requirement for intensive daily monitoring, accelerating the demand for SMBG devices.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the U.S. self-monitoring blood glucose devices market is segmented into hospitals, ambulatory surgical centers, diagnostic centers, home care, and other end users. Hospitals accounted for the revenue share of 21.5% in 2024.
 

• Hospitals serve as primary centers for diabetes care, offering diagnosis, treatment initiation, and ongoing monitoring. They have trained medical professionals and advanced diagnostic tools that ensure timely and accurate intervention.
• Hospitals are also ideal environments for deploying cutting-edge diabetes technologies such as continuous glucose monitors (CGMs), and insulin pump, making them central to the adoption of high-tech SMBG solutions.
   
• Financial support helps strengthen hospitals' role in this. Through Medicare and other reimbursement programs, hospitals get support for integrating advanced diabetes devices into patient care. With the rising number of diabetes related hospitalizations and the increasing prevalence of diabetes in the U.S., hospitals are well-positioned to lead in device deployment.
   
• Additionally, hospitals have robust infrastructure and clinical expertise to manage complex cases, such as gestational diabetes or patients in intensive care units, where continuous monitoring is essential. Their ability to deliver comprehensive care using SMBG devices supports their growth in the market. With substantial resources, skilled personnel, and access to innovative technologies, hospitals continue to be a rapidly growing segment in the expansion of the U.S. SMBG devices market.
   

U.S. Self-monitoring Blood Glucose Devices Market Share

• The U.S. self-monitoring blood glucose devices industry is competitive, top five companies such as F. Hoffmann-La Roche, Abbott Laboratories, Ascensia Diabetes Care Holdings, LifeScan, and Sinocare hold most of the market share accounting for approximately 27.8% in 2024. Their dominance is stimulated by extensive product portfolios, robust distribution networks, regulatory compliance, and continuous innovation. Among them, LifeScan and F. Hoffmann-La Roche stand out for their user-friendly glucometers and test strips, which are widely adopted in both clinical and home settings, giving them a competitive edge.
   
• Beyond hospitals and clinics, the growing demand for home-based SMBG devices is creating new opportunities for both established and emerging players. Consumers increasingly prefer portable, easy-to-use devices that offer quick results and privacy. This shift is further supported by advancements in Bluetooth-enabled meters, smartphone integration, and cloud-based data tracking, making self-monitoring more convenient and effective.
   
• Emerging players in SMBG space are adopting diverse strategies to gain market share. These include focusing on next-generation glucometers with smartphone connectivity, AI-driven analytics, and personalized feedback. Many are also forming strategic partnerships with digital health platforms, pharmacies, and healthcare providers to enhance accessibility, reduce costs, and improve patient adherence.
   

U.S. Self-monitoring Blood Glucose Devices Market Companies

Few of the prominent players operating in the U.S. self-monitoring blood glucose devices industry include:

• Abbott Laboratories
• AgaMatrix
• All Medicus
• Arkray
• Ascensia Diabetes Care Holdings
• B. Braun Melsungen
• Bionime Corporation
• DarioHealth
• F. Hoffmann-La Roche
• LifeScan
• Nova Biomedical
• Omnis Health
• Sanofi
• Sinocare
• Ypsomed Holding
   
• F. Hoffmann-La Roche

F. Hoffmann-La Roche is a healthcare company known for its reliable and user-friendly blood glucose monitoring systems, with a market share of 9.5% in 2024. It emphasizes innovation and digital integration to support effective self-management of diabetes.
 

• Abbott Laboratories 

Abbott Laboratories is a global healthcare company recognized for its contributions to diabetes management through innovative glucose monitoring technologies. Its solutions focus on user comfort, accuracy, and digital integration, helping individuals track and manage their glucose levels with greater ease and confidence.
 

• LifeScan

LifeScan designs advanced patient-friendly blood glucose monitoring systems that help increase patient confidence and control.
 

U.S. Self-monitoring Blood Glucose Devices Industry News:

• In March 2024, Nova Biomedical launched the New Generation StatStrip Glucose Hospital Meter System in the U.S., featuring enhanced usability, improved cybersecurity, and FDA clearance for use with critically ill patients, reinforcing the company's commitment to advancing healthcare technology and reliable glucose monitoring in hospital settings.
   

The U.S. self-monitoring blood glucose devices market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million and from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Self-monitoring blood glucose meters
• Consumables
  • Testing strips
  • Lancets

Market, By Application

• Type 1 diabetes
• Type 2 diabetes
• Gestational diabetes

Market, By End Use

• Hospital
• Ambulatory surgical centers        
• Diagnostic centers
• Homecare
• Other end use